
Novo Nordisk added approximately 2,000 employees in 2025 following major layoffs of 7,800 workers last year under CEO Mike Doustdar. The Danish pharmaceutical company is reshaping its workforce strategically, focusing hiring on priority areas supporting diabetes and obesity drug portfolios. The restructuring aims to streamline operations, maintain cost controls, and strengthen capabilities in high-growth segments amid rising global demand for weight-loss treatments and intensifying competition.